Investor Overview

Corporate Profile

vTv Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

Presentations

Date Title
More >>

Recent News

Date Title
Toggle Summary vTv Therapeutics to Participate in Upcoming Canaccord Genuity and Solebury Trout Conferences
HIGH POINT, N.C. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for diabetes and Alzheimer’s disease, today announced that it will be participating in the
View HTML
Toggle Summary vTv Therapeutics Announces 2019 Second Quarter Financial Results and Update
HIGH POINT, N.C. , July 31, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter that ended June 30, 2019 , and provided an update on recent achievements and upcoming events. “We made significant progress during the second quarter,”
View HTML
Toggle Summary vTv Therapeutics to Present at 2019 Alzheimer’s Association International Conference
HIGH POINT, N.C. --(BUSINESS WIRE)--Jul. 15, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will make an oral
View HTML
Toggle Summary vTv Therapeutics Initiates Phase 2 Clinical Trial Evaluating Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes
HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 27, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the first patient has been screened for the phase 2 proof of concept study evaluating the safety and efficacy of azeliragon in patients with mild Alzheimer's disease and type 2 diabetes.
View HTML
More >>
Upcoming Events
More events are coming soon.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever vTv Therapeutics Inc. posts new information to the site.

Copyright West LLC. Minimum 15 minutes delayed.

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.